Spero (SPRO) CMO Debra Zack Receives Equity Awards

What Happened

• Debra Zack, Chief Medical Officer of Spero Therapeutics (SPRO), received equity awards on August 3, 2026: 162,311 restricted stock units (RSUs) and 324,675 derivative awards (total 486,986 units). Each award was granted at $0.00 (no cash paid).
• These are grants (not open‑market purchases or sales) and do not represent immediately tradable shares; they vest over time per the company plan.

Key Details

• Transaction date: August 3, 2026; Filing date (Form 4): August 6, 2026 (three days after the transaction).
• Price: $0.00 for both grants; combined award = 486,986 units.
• Shares owned after transaction: not disclosed in the provided filing summary.
• Footnotes:
  • F1: 162,311 RSUs — each RSU converts to one share on vesting; vest in four equal annual installments beginning August 3, 2027, subject to continued service.
  • F2: 324,675 derivative award — underlying shares vest 25% on August 3, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service.
• Timeliness: Form 4 was filed Aug 6 for an Aug 3 transaction; Form 4s are generally required within two business days, so this filing may be later than that standard.

Context

• RSUs and the listed derivative award are typical executive compensation meant to retain employees; they are not immediate insider purchases or sales and do not necessarily signal a buy/sell sentiment.
• Until vesting occurs, these units are subject to forfeiture if the reporting person leaves before vesting dates; once vested and issued, they could be sold (subject to company policy and securities rules).